Your SlideShare is downloading. ×
Myasthenia Gravis..A quick guide to management
Myasthenia Gravis..A quick guide to management
Myasthenia Gravis..A quick guide to management
Myasthenia Gravis..A quick guide to management
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Myasthenia Gravis..A quick guide to management

1,364

Published on

Myasthenia Gravis..A quick guide to management …

Myasthenia Gravis..A quick guide to management
http://yassermetwally.com
http://yassermetwally.net

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
1,364
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
54
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Myasthenia gravis: A quick guide to management 1 MYASTHENIA GRAVIS: A QUICK GUIDE TO MANAGEMENT Professor Yasser Metwally… www.yassermetwally.com Epidemiology Incidence 1:20,000. 5 - 7% familial Age of onset May start at any age. Rare before 15 or after 70. 60 per cent has onset between the ages of 20 and 40 Due to the increased proportion of older persons, more older patients are found to have MG Early onset: onset before 50 yo Predominantly female Late onset: onset after 50 yo likely to be more severe myopathy is more common Effect of acetylcholinesterase inhibitors is often temporary. Plasma exchange has more complications in the elderly Result of thymectomy is poorer Classification after Ossreman & Genkins Adult MG Group I: Ocular (20%) Group IIA: Mild generalized (30%) Group III: Acute fulminating (11%), rapid onset, early respiratory involvement, high mortality. Group IV: Late Severe (9%), > 2 years after onset. Transient Neonatal MG: 1/6 born to MG mother. Last a few weeks. Congenital Myasthenic Syndrome: Testing Anti-acetylcholine receptor Ab: Present in 80% of patient Tindall: Ocular 55% positive Mild Generalized 80% positive
  • 2. Myasthenia gravis: A quick guide to management 2 Moderately severe or acute 100% positive Chronic severe 89% In remission 24% Antibodies to striated muscle (StrAb) Positive in 30% of all adult onset MG. Highly associated with thymoma Positive in 80% of MG patients with thymoma Positive in 24% of patients with thymoma without MG. Seronegativity does not exclude thymoma. Most useful as a marker of thymoma in patients with MG onset before age 40. A progressive rise in StrAbs titer after resection of thymoma is a good indicator of tumor recurrence. A valuable marker in middle-aged or elderly patients with mild MG, where they can be the only serologic abnormality. False positives are rare in patients without MG and/or thymoma. Sometimes positive in patients with rheumatoid arthritis who are treated with penicillamine, in 3-5% of patients with Lambert-Eaton myasthenic syndrome, and in recipients of bone marrow allografts with graft vs. host disease. Thymoma 15% of patient has thymoma, 50% has thymic hyperplasia. Antiskeletal muscle Ab are detected in 90% of patients with thymoma. CT Chest detect over 85% of thymoma. Removal of thymoma produces a delayed improvement of MG 6 - 24 months later. Sustained improvement in > 50%, probably less in older patients. No known long-term side effects. Tensilon test (Edrophonium) Given in incremental doses. Start with 2 mg, observe the response for 45 to 60 seconds, followed by doses of 3 and 5 mg and observation for a clinical response for 1 to 2 minutes following each dose. During the injection, patients often experience 1 to 3 minutes of increased salivation, mild sweating, perioral fasciculations and mild nausea. Hypotension and bradycardia are extremely rare but precautions should be taken. Atropine sulfate (0.6 mg intramuscular or intravenously) should be available in case of an emergency. Positive means unequivocally improvement of weakness. Slight to moderate improvement in muscle strength must be interpreted with extreme caution. Mild to moderate clinical improvement after tensilon has been reported in: brain stem lesions, oculomotor palsy due to cerebral artey aneurysm, diabetic abducens paresis and even in normal control subjects. Electrophysiology: Repetitive stimulation at 3 hertz. >10% decrement of compound action potential. Single fiber EMG: Increased jitter: jitter is the varying time interval between the triggered muscle action potential in 2 muscle fibers within the same motor unit. Positive in over 90%.
  • 3. Myasthenia gravis: A quick guide to management 3 Treatment Principles of treatment Onset before age 60 Thymectomy, pretreat with plasmapheresis, cholinesterase inhibitors If response unsatisfactory before or after thymectomy, consider high dose daily prednisone and/or other immunosuppressive agents Onset after age 60 Cholinesterase inhibitors with prednisone, azathioprine or other immunosuppressant Plasmapheresis for severe exacerbations Consider thymectomy Anticholinesterase useful in all forms For patient with thymoma, thymectomy is indicated in all ages. They may spread in the mediastinum. Plasmapharesis is effective, but practical only on a short term basis. Pyridostigmine (Mestinon) Tab: 60 mg, half life 4 hrs, take 1 q 4 while awake Time Span: 180 mg, irregular absorption, use at night only. IV: 2 mg = 60 mg of oral dose Side effect: diarrhea, treat with Lomotil or Imodium Steroid treatment Indications: Insufficient control w Mestinon Diplopia rarely respond to Mestinon alone Older male Start at 100 mg to avoid treatment failure. After remission obtained, switch to alternate day dose, slow taper over 6 to 12 months. Patient may get weaker initially. Exacerbation is common. Azathioprine (Imuran) Initial dose 2-3 mg/kg/day. Mertens: Complete remission 40%, partial remission 51%, minimal improvement 6.4%, no effect in 2.6%. Improvement begins in 2-3 months, peaks in 6-15 months. Keep WBC above 3000/ml. Monitor liver function weekly X 3 months, then 2x/month. Sometimes used in combination with steroid. If above treatment fails, consider Cyclosporine (Sandimmune)
  • 4. Myasthenia gravis: A quick guide to management 4 5 mg/kg/day, in bid dose. Monitor BP, renal function, Cyclosporine level, Amylase, Cholesterol. May cause nephropathy, hypertension, hirsutism, liver function abnormality, opportunistic infection, may increase risk of malignancy. Plasma Exchange: short term improvement Human Immune Globulin: Probably effective Drugs that may adversely affect MG Antibiotics Aminoglycosides: Neomycin, Gentamycin Peptide: Polymyxin B, Colistin Other: tetracycline, Clindamycin, Erythromycin, Ampicillin Neuromuscular blockers: Botulinum Toxin Cardiac drugs: Quinine, Quinidine, Procanamide, Lidocaine, Beta blockers, Calcium Channel Blockers Miscellaneous: Dilantin, Oxytocin, Lithium, Magnesium, Diazapam, D penicillamine, Cloroquine, Interferon Corticosteroids may initially produce worsening of MG. Other causes of exacerbation Febrile illness Thyroid disease Heat Pregnancy Major Physical Stress References Myasthenia Gravis [Full text]

×